CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 44 enrolled
Drug / intervention
Activator LFD-2100device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04500821
NCT04500821N/ACompleted
CompareCT.gov

Evaluation of the LipiFlow System With a New Activator (Model LFD-2100)

Johnson & Johnson Surgical Vision, Inc.·interventional·Posted Aug 5, 2020·Updated Jan 24, 2022

In Brief

A clinical study evaluating Activator LFD-2100 for Meibomian Gland Dysfunction. Completed, enrolled 44 participants across 3 sites.

Detailed Summary

Minimum 50 eyes and up to 100 eyes will be treated in this prospective, open-label clinical study. The investigator or designee will perform LipiFlow treatment with the Activators LFD-2100 on both eyes of a subject. The data from the treatment reports generated by the LipiFlow console and from the questionnaire will be used to assess the clinical utilization of the Activator LFD-2100. This study will be conducted in up to four sites in the USA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeibomian Gland Dysfunction
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 5, 2020
Enrollment StartOct 2, 2020
Primary CompletionOct 30, 2020
TodayJul 2, 2026
Enrollment to primary: 28 daysPosted 5.9 years ago

Interventions

Activator LFD-2100device

LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD